世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - パイプラインレビュー 2018年上半期

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - パイプラインレビュー 2018年上半期
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018

レポートタイトル Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 55 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
Alkermes Plc
Celgene Corp
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEL-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
Featured News & Press Releases
Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta
Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis
Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage
Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta
Jun 09, 2017: EMA reviews multiple sclerosis medicine Zinbryta
May 03, 2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program
Apr 10, 2017: Biogen's Zinbryta accepted for use in NHS Scotland
Mar 27, 2017: Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Alkermes Plc, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Medicenna Therapeutics Corp, H1 2018
Pipeline by Nektar Therapeutics, H1 2018
Pipeline by Philogen SpA, H1 2018
Dormant Products, H1 2018
Loading....